This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cramer's 'Mad Money' Recap: A Market of Mixed Signals

Lightening Round

Here's what Cramer had to say about callers' stocks during the "Lightning Round":

Wendy's Company (WEN): "I think Wendy's is cheap and it's a buy here."

RR Donnelley (RRD): "This used to be a great growth company but I don't see any growth."

Sprint Nextel (S): "Don't let Sprint go. It's reasonable for it to pull back, but if that happens you buy more. Sprint goes higher."

Lennar (LEN): "Buy half here and the rest on a pullback. "

Rovi Corporation (ROVI): "No, no. They failed to deliver and I don't like the growth prospects there."

Bank of America (BAC): "It's not my favorite. They don't have any earnings momentum. It'll come back eventually."

Opko Health (OPK): "It has not acted well. I need to hear from their CEO again. Otherwise, don't buy. "

Weeding Through Possibilities

In the "Executive Decision" segment, Cramer spoke with Charles Foster, chairman, president and CEO of Charles River Labs (CRL - Get Report), a company that helps big pharma weed through thousands of drug possibilities to find the chosen few with high probabilities of success.

Foster explained that Charles River changes the value proposition for big drug makers by saving them both time and money through outsourcing much of their pre-clinical testing. In times past, he said, if a drug maker had eight drug variants, they'd develop all eight. Now the process must be refined to a single candidate as it's simply too costly to develop more than one.

Charles River aims to partner with the majority of major drug makers, said Foster, and outsource the majority of their pre-clinical testing work. He predicted growth for the company in the mid-single digits for the next three years, with profit margins hovering around 20%.

Cramer said while it's often hard to invest in biotech companies, Charles River lowers the risk by serving all of them. He is also a big fan of the company's share buyback program, which has already retired 28% of it's outstanding shares.

No Huddle Offense

In his "No Huddle Offense" segment, Cramer answered the question on every investor's mind: Does the selection of Rep. Paul Ryan as running mate to presumptive Republican presidential candidate Mitt Romney matter to the markets? In a word, no.

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
CRL $77.40 0.00%
REGN $480.09 0.00%
AAPL $130.28 0.00%
FB $81.53 0.00%
GOOG $565.06 0.00%


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs